CEO Comments

WELL-POSITIONED FOR THE NEXT PHASE Our focus during the third quarter has mainly been on production and financing. We are now producing on a large scale in our production line, while having secured financing to intensify our investments in preparative chromatography and deliver on the order book we are starting to build. During the third quarter, we received several orders for the evaluation of NLAB Saga®, our silica for preparative chromatography, including one order from

ORDER FROM INSULIN MANUFACTURERS LAYS FOUNDATION FOR CHARGING FORWARD During the quarter, we launched our product line NLAB Saga® for preparative chromatography, after finalizing large volumes of the first products at the large-scale production facility. NLAB Saga® has initially been very well received by customers, which was shown by an order from one of the world’s largest insulin manufacturers in August, for evaluation of the product at production scale. If the products meet the customer’s

A NEW CHAPTER BEGINS  On March 29, 2022, a new chapter in Nanologica’s history began – as listed on a regulated market. By listing the share on Nasdaq Stockholm Main Market, we get an increased exposure and a better opportunity to attract institutional and international owners.  At the same time, we are now launching our products for preparative chromatography. The big event of the quarter was the change of lists to Nasdaq Stockholm Main Market,